Vanda Salutari

3.9k total citations
110 papers, 1.5k citations indexed

About

Vanda Salutari is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Vanda Salutari has authored 110 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Reproductive Medicine, 48 papers in Oncology and 30 papers in Obstetrics and Gynecology. Recurrent topics in Vanda Salutari's work include Ovarian cancer diagnosis and treatment (70 papers), PARP inhibition in cancer therapy (28 papers) and Endometrial and Cervical Cancer Treatments (28 papers). Vanda Salutari is often cited by papers focused on Ovarian cancer diagnosis and treatment (70 papers), PARP inhibition in cancer therapy (28 papers) and Endometrial and Cervical Cancer Treatments (28 papers). Vanda Salutari collaborates with scholars based in Italy, United States and Spain. Vanda Salutari's co-authors include Giovanni Scambia, Gabriella Ferrandina, Francesco Legge, Domenica Lorusso, Gian Franco Zannoni, A. C. Testa, Marco Petrillo, Giacomo Corrado, Eleonora Palluzzi and Camilla Nero and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Vanda Salutari

98 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vanda Salutari Italy	23	722	555	412	333	291	110	1.5k
Chad M. Michener United States	24	562 0.8×	382 0.7×	498 1.2×	411 1.2×	403 1.4×	98	1.6k
F. Raja United Kingdom	6	781 1.1×	497 0.9×	207 0.5×	290 0.9×	230 0.8×	12	1.2k
Marta A. Crispens United States	25	723 1.0×	498 0.9×	447 1.1×	568 1.7×	177 0.6×	62	1.8k
Hidekatsu Nakai Japan	21	667 0.9×	445 0.8×	418 1.0×	323 1.0×	191 0.7×	75	1.3k
Gabriella Parma Italy	19	869 1.2×	617 1.1×	596 1.4×	296 0.9×	350 1.2×	53	1.6k
Sabrina Chiara Cecere Italy	20	525 0.7×	615 1.1×	261 0.6×	428 1.3×	227 0.8×	71	1.4k
Rosalind Glasspool United Kingdom	25	753 1.0×	722 1.3×	375 0.9×	842 2.5×	181 0.6×	86	1.9k
A.G.J. van der Zee Netherlands	24	434 0.6×	528 1.0×	318 0.8×	593 1.8×	301 1.0×	53	1.6k
Toshiko Jobo Japan	20	1.1k 1.5×	636 1.1×	717 1.7×	294 0.9×	410 1.4×	70	1.8k
Joanne Rutgers United States	23	555 0.8×	391 0.7×	848 2.1×	381 1.1×	341 1.2×	53	1.8k

Countries citing papers authored by Vanda Salutari

Since Specialization

Citations

This map shows the geographic impact of Vanda Salutari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanda Salutari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanda Salutari more than expected).

Fields of papers citing papers by Vanda Salutari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanda Salutari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanda Salutari. The network helps show where Vanda Salutari may publish in the future.

Co-authorship network of co-authors of Vanda Salutari

This figure shows the co-authorship network connecting the top 25 collaborators of Vanda Salutari. A scholar is included among the top collaborators of Vanda Salutari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanda Salutari. Vanda Salutari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Joyce F., Nicoletta Colombo, Amit M. Oza, et al.. (2025). ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. Journal of Clinical Oncology. 43(26). 2897–2907. 5 indexed citations

Tesei, Marco, Barbara Costantini, Camelia Alexandra Coadǎ, et al.. (2025). Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: A collaborative multi-institutional study. European Journal of Surgical Oncology. 52(1). 111161–111161.

Loverro, Matteo, Vanda Salutari, Diana Giannarelli, et al.. (2025). Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence. ESMO Open. 10(2). 104119–104119.

Dańska-Bidzińska, Anna, Vanda Salutari, Ali̇ Ayhan, et al.. (2024). 737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study. Annals of Oncology. 35. S561–S561. 1 indexed citations

Fagotti, Anna, Barbara Costantini, Francesco Fanfani, et al.. (2024). Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18). Journal of Clinical Oncology. 43(7). 852–860. 10 indexed citations

Musacchio, Lucia, Serena Maria Boccia, Cláudia Marchetti, et al.. (2023). Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors. International Journal of Gynecological Cancer. 33(6). 922–928. 1 indexed citations

Salutari, Vanda, Cláudia Marchetti, Viola Ghizzoni, et al.. (2023). #881 The NUVOLA TRIAL: neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study. A430.3–A431.

Liu, Joyce F., Nicoletta Colombo, Amit M. Oza, et al.. (2023). ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma (039). Gynecologic Oncology. 176. S33–S35. 4 indexed citations

Vizzielli, Giuseppe, Federica Nardelli, Barbara Costantini, et al.. (2023). ASO Visual Abstract: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor—A Single-Institution Experience (ID:PARROT Trial). Annals of Surgical Oncology. 31(3). 1808–1809. 1 indexed citations

10.

Musacchio, Lucia, Vanda Salutari, Sandro Pignata, et al.. (2022). 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer. International Journal of Gynecological Cancer. 32. A347–A348.

11.

Salutari, Vanda, Lucia Musacchio, Sandro Pignata, et al.. (2022). 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). International Journal of Gynecological Cancer. 32. A356–A356.

12.

Rosati, Andrea, Camilla Fedele, Anna Fagotti, et al.. (2022). Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact. European Journal of Obstetrics & Gynecology and Reproductive Biology. 273. 1–6. 3 indexed citations

13.

Marchetti, Cláudia, Riccardo Tudisco, Vanda Salutari, et al.. (2021). Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial). International Journal of Gynecological Cancer. 31(8). 1175–1178. 5 indexed citations

14.

Russo, Luca, Giacomo Avesani, Benedetta Gui, et al.. (2021). Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know. Korean Journal of Radiology. 22(8). 1310–1310. 6 indexed citations

15.

Nero, Camilla, Francesca Ciccarone, Antonella Pietragalla, et al.. (2021). Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. Cancers. 13(6). 1298–1298. 30 indexed citations

16.

Giudice, Elena, Vanda Salutari, Caterina Ricci, et al.. (2021). Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review. Critical Reviews in Oncology/Hematology. 168. 103542–103542. 8 indexed citations

17.

Chieffo, Daniela Pia Rosaria, Barbara Costantini, Silvia Riccardi, et al.. (2021). The Psychological Impact on 472 Gynecological Cancer Patients: First Diagnosis vs. Disease Recurrence. 6(1).

18.

Gadducci, Angiolo, Giovanni Aletti, Fabio Landoni, et al.. (2020). Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). Tumori Journal. 107(2). 100–109. 8 indexed citations

19.

Caruso, Giuseppe, Lucia Musacchio, Giusi Santangelo, et al.. (2020). Ovarian Cancer Metastasis to the Breast: A Case Report and Review of the Literature. Case Reports in Oncology. 13(3). 1317–1324. 8 indexed citations

20.

Paragliola, Rosa Maria, Francesco Torino, Vanda Salutari, et al.. (2013). “Occult” ovarian Leydig cell tumor: when laboratory tells more than imaging. Endocrine. 46(2). 351–354. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact